SCHEMBL355041

SCHEMBL355041

NC(CCS(=O)(=O)O)C1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.41
TP53 P04637 1/20 0.36
KDM4E B2RXH2 1/20 0.35
GMNN O75496 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
DPP4 P27487 7/20 0.35
ALDH1A1 P00352 1/20 0.34
DPP7 Q9UHL4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28324445 1.00 EPHX1 (0.41) EPHX1TP53KDM4EGMNNLMNA
SCHEMBL22551590 0.90 LMNA (0.37) LMNABLM
SCHEMBL5844523 0.89 EPHX1 (0.38) EPHX1TP53KDM4EGMNNLMNA
SCHEMBL27857861 0.82 EPHX1 (0.38) EPHX1TP53DPP4
SCHEMBL28324333 0.80 EPHX1 (0.43) EPHX1TP53KDM4EGMNNLMNA
SCHEMBL3500350 0.80 EPHX1 (0.43) EPHX1TP53KDM4EGMNNLMNA
SCHEMBL11803465 0.78 EPHX1 (0.42) EPHX1TP53KDM4EGMNNLMNA
SCHEMBL29074463 0.78 DPP4 (0.39) DPP4
SCHEMBL23781756 0.78 S1PR2 (0.35)
SCHEMBL28901368 0.77 LMNA (0.31) LMNABLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735620-A1 METHODS AND FORMULATIONS FOR DENATURING DNA Illumina, Inc. (US) 2026-05-06 EP claimed
WO-2025003421-A1 METHODS AND FORMULATIONS FOR DENATURING DNA ILLUMINA, INC. (US) 2025-01-02 WO claimed
EP-3280444-B1 METHODS FOR PURIFYING HETERODIMERIC MULTISPECIFIC ANTIBODIES FROM PARENTAL HOMODIMERIC ANTIBODY SPECIES ADIMAB LLC (US) 2024-05-08 EP claimed
EP-4263690-A1 LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME FRS Group, LLC (US) 2023-10-25 EP claimed
WO-2022132962-A1 LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME FRS GROUP, LLC (US) 2022-06-23 WO claimed
EP-3762339-A1 METHODS AND COMPOSITIONS TO REDUCE AZOLES AND AOX CORROSION INHIBITORS BL Technologies, Inc. (US) 2021-01-13 EP claimed
US-20180079797-A1 METHODS FOR PURIFYING HETERODIMERIC MULTISPECIFIC ANTIBODIES FROM PARENTAL HOMODIMERIC ANTIBODY SPECIES ADIMAB, LLC 2018-03-22 US claimed
EP-3280444-A1 METHODS FOR PURIFYING HETERODIMERIC MULTISPECIFIC ANTIBODIES FROM PARENTAL HOMODIMERIC ANTIBODY SPECIES Adimab, LLC (US) 2018-02-14 EP claimed
WO-2016196207-A1 COMPOSITIONS, APPARATUS, AND METHODS FOR DETERMINING HARDNESS OF WATER AND MAGNESIUM ION IN AN ANALYTE COMPOSITION WATER LENS, LLC. (US) 2016-12-08 WO claimed
WO-2016164708-A1 METHODS FOR PURIFYING HETERODIMERIC MULTISPECIFIC ANTIBODIES FROM PARENTAL HOMODIMERIC ANTIBODY SPECIES ADIMAB, LLC (US) 2016-10-13 WO claimed
EP-3016965-A1 ALKALINE ACTIVATION FOR IMMOBILIZATION OF DNA TAGGANTS Applied DNA Sciences Inc. (US) 2016-05-11 EP claimed
EP-3003385-A1 ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR Innova Biosciences Limited (GB) 2016-04-13 EP claimed
WO-2015002677-A1 ALKALINE ACTIVATION FOR IMMOBILIZATION OF DNA TAGGANTS APPLIED DNA SCIENCES INC. (US) 2015-01-08 WO claimed
WO-2014191560-A1 ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR INNOVA BIOSCIENCES LTD (GB) 2014-12-04 WO claimed
WO-2014143864-A2 METHODS OF DETECTING INFLUENZA VIRUS UNIVERSITY OF CINCINNATI (US) 2014-09-18 WO claimed
CN-1753961-B Cmp composition comprising a sulfonic acid and a method for polishing noble metals CABOT MICROELECTRONICS CORP 2010-08-11 CN claimed
EP-1740284-A2 SEPARATIONS PLATFORM BASED UPON ELECTROOSMOSIS-DRIVEN PLANAR CHROMATOGRAPHY Perkinelmer Las, Inc. (US) 2007-01-10 EP claimed
CN-1753961-A Cmp composition comprising a sulfonic acid and a method for polishing noble metals CABOT MICROELECTRONICS CORP (US) 2006-03-29 CN claimed
WO-2005092013-A2 SEPARATIONS PLATFORM BASED UPON ELECTROOSMOSIS-DRIVEN PLANAR CHROMATOGRAPHY PERKINELMER LAS, INC. (US) 2005-10-06 WO claimed
JP-62175668-A None JP disclosed
EP-4735620-A1 METHODS AND FORMULATIONS FOR DENATURING DNA Illumina, Inc. (US) 2026-05-06 EP disclosed
US-12379345-B2 Method of purity determination by capillary electrophoresis BRISTOL-MYERS SQUIBB COMPANY (US) 2025-08-05 US disclosed
EP-4520798-A1 POLISHING COMPOSITION AND METHOD FOR POLISHING SUBSTRATE USING THE COMPOSITION Fujimi Incorporated (JP) 2025-03-12 EP disclosed
WO-2025003421-A1 METHODS AND FORMULATIONS FOR DENATURING DNA ILLUMINA, INC. (US) 2025-01-02 WO disclosed
WO-2024145200-A1 CHARGE BALANCED POLYMERS FOR INDUSTRIAL WATER APPLICATIONS BL TECHNOLOGIES, INC. (US) 2024-07-04 WO disclosed
EP-4367235-A1 COMPOSITIONS AND METHODS FOR DETECTING GENETIC FEATURES Singular Genomics Systems, Inc. (US) 2024-05-15 EP disclosed
EP-3280444-B1 METHODS FOR PURIFYING HETERODIMERIC MULTISPECIFIC ANTIBODIES FROM PARENTAL HOMODIMERIC ANTIBODY SPECIES ADIMAB LLC (US) 2024-05-08 EP disclosed
EP-4359786-A1 MASS SPECTROMETRY-COMPATIBLE PH GRADIENT BUFFER SYSTEM Phenomenex, Inc. (US) 2024-05-01 EP disclosed
WO-2024057324-A1 PLASMA-ACTIVATED COMPOSITIONS AND METHODS OF USE THEREOF NOVA PLASMA LTD. (IL) 2024-03-21 WO disclosed
WO-2023240090-A1 ENHANCING CLUSTERING EFFICIENCY AND KINETICS ILLUMINA, INC. (US) 2023-12-14 WO disclosed
US-20230393094-A1 METHOD OF PURITY DETERMINATION BY CAPILLARY ELECTROPHORESIS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-12-07 US disclosed
EP-4271839-A1 PHASE PROTECTIVE REAGENT FLOW ORDERING Singular Genomics Systems, Inc. (US) 2023-11-08 EP disclosed
EP-4263690-A1 LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME FRS Group, LLC (US) 2023-10-25 EP disclosed
US-20230265501-A1 PHASE PROTECTIVE REAGENT FLOW ORDERING FIRST-CITIZENS BANK & TRUST COMPANY 2023-08-24 US disclosed
EP-4153606-A2 METHODS OF SEQUENCING COMPLEMENTARY POLYNUCLEOTIDES Singular Genomics Systems, Inc. (US) 2023-03-29 EP disclosed
EP-4142740-A1 COMPOSITIONS AND METHODS OF USE THEREOF Synedgen, Inc. (US) 2023-03-08 EP disclosed
EP-4117682-A1 MODIFIED NUCLEOTIDES AND USES THEREOF Singular Genomics Systems, Inc. (US) 2023-01-18 EP disclosed
WO-2023283090-A1 COMPOSITIONS AND METHODS FOR DETECTING GENETIC FEATURES Singular Genomics Systems, Inc. (US) 2023-01-12 WO disclosed
WO-2022271853-A1 MASS SPECTROMETRY-COMPATIBLE PH GRADIENT BUFFER SYSTEM PHENOMENEX, INC. (US) 2022-12-29 WO disclosed
WO-2022272150-A2 LINKED TRANSCRIPT SEQUENCING Singular Genomics Systems, Inc. (US) 2022-12-29 WO disclosed
WO-2022197942-A1 PHASE PROTECTIVE REAGENT FLOW ORDERING Singular Genomics Systems, Inc. (US) 2022-09-22 WO disclosed
WO-2022132962-A1 LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME FRS GROUP, LLC (US) 2022-06-23 WO disclosed
WO-2021221656-A1 COMPOSITIONS AND METHODS OF USE THEREOF SYNEDGEN, INC. (US) 2021-11-04 WO disclosed
WO-2021222727-A1 COMPOSITIONS AND METHODS OF USE THEREOF SYNEDGEN, INC. (US) 2021-11-04 WO disclosed
EP-3803387-A1 MITOCHONDRIAL CONDUCTANCE INHIBITORS AND METHODS OF USE THEREOF The Regents of The University of California (US) 2021-04-14 EP disclosed
US-20210047387-A1 METHODS FOR PURIFYING HETERODIMERIC MULTISPECIFIC ANTIBODIES FROM PARENTAL HOMODIMERIC ANTIBODY SPECIES ADIMAB LLC (US) 2021-02-18 US disclosed
EP-3762339-A1 METHODS AND COMPOSITIONS TO REDUCE AZOLES AND AOX CORROSION INHIBITORS BL Technologies, Inc. (US) 2021-01-13 EP disclosed
EP-3759461-A1 SAMPLE PREPARATION FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING Selux Diagnostics, Inc. (US) 2021-01-06 EP disclosed
US-10787500-B2 Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species ADIMAB, LLC (US) 2020-09-29 US disclosed
EP-3440223-A1 PROCESS FOR CELL LYSIS AND NUCLEIC ACID AMPLIFICATION 3M Innovative Properties Company (US) 2019-02-13 EP disclosed
EP-3430160-A1 DETECTION OF CELLS IN A LIQUID SAMPLE Delta Instruments B.V. (NL) 2019-01-23 EP disclosed
WO-2018140590-A1 SEFT-LABELING MINIPROTEINS AND CONJUGATES COMPRISING THEM MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2018-08-02 WO disclosed
US-20180079797-A1 METHODS FOR PURIFYING HETERODIMERIC MULTISPECIFIC ANTIBODIES FROM PARENTAL HOMODIMERIC ANTIBODY SPECIES ADIMAB, LLC 2018-03-22 US disclosed
CN-107735069-A Dental adhesive 登特斯普伊德特雷有限公司 2018-02-23 CN disclosed
EP-3280444-A1 METHODS FOR PURIFYING HETERODIMERIC MULTISPECIFIC ANTIBODIES FROM PARENTAL HOMODIMERIC ANTIBODY SPECIES Adimab, LLC (US) 2018-02-14 EP disclosed
CN-105378466-B Anion sensors 株式会社日立高新技术 2017-11-24 CN disclosed
WO-2017176469-A1 PROCESS FOR CELL LYSIS AND NUCLEIC ACID AMPLIFICATION 3M INNOVATIVE PROPERTIES COMPANY (US) 2017-10-12 WO disclosed
WO-2017158431-A1 DETECTION OF CELLS IN A LIQUID SAMPLE DELTA INSTRUMENTS B.V. (NL) 2017-09-21 WO disclosed
EP-3212781-A2 SERINE PROTEASES Danisco US Inc. (US) 2017-09-06 EP disclosed
EP-3212662-A1 SERINE PROTEASES Danisco US Inc. (US) 2017-09-06 EP disclosed
WO-2016196207-A1 COMPOSITIONS, APPARATUS, AND METHODS FOR DETERMINING HARDNESS OF WATER AND MAGNESIUM ION IN AN ANALYTE COMPOSITION WATER LENS, LLC. (US) 2016-12-08 WO disclosed
WO-2016164708-A1 METHODS FOR PURIFYING HETERODIMERIC MULTISPECIFIC ANTIBODIES FROM PARENTAL HOMODIMERIC ANTIBODY SPECIES ADIMAB, LLC (US) 2016-10-13 WO disclosed
EP-1836161-B1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES BHI LTD PARTNERSHIP (CA) 2016-07-20 EP disclosed
EP-1836161-B1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES BHI LTD PARTNERSHIP (CA) 2016-07-20 EP disclosed
EP-3016965-A1 ALKALINE ACTIVATION FOR IMMOBILIZATION OF DNA TAGGANTS Applied DNA Sciences Inc. (US) 2016-05-11 EP disclosed
WO-2016069548-A2 SERINE PROTEASES DANISCO US INC. (US) 2016-05-06 WO disclosed
WO-2016069552-A1 SERINE PROTEASES DANISCO US INC. (US) 2016-05-06 WO disclosed
WO-2016066885-A1 A METHOD TO MEASURE PHOSPHONATES AQSENS OY (FI) 2016-05-06 WO disclosed
EP-3003385-A1 ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR Innova Biosciences Limited (GB) 2016-04-13 EP disclosed
US-9195215-B2 Holographic medium having a protective layer BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-11-24 US disclosed
EP-2920586-A1 IONIC STRENGTH-MEDIATED pH GRADIENT ION EXCHANGE CHROMATOGRAPHY F. Hoffmann-La Roche SA (CH) 2015-09-23 EP disclosed
WO-2015002677-A1 ALKALINE ACTIVATION FOR IMMOBILIZATION OF DNA TAGGANTS APPLIED DNA SCIENCES INC. (US) 2015-01-08 WO disclosed
WO-2014191560-A1 ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR INNOVA BIOSCIENCES LTD (GB) 2014-12-04 WO disclosed
US-20140329746-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2014-11-06 US disclosed
US-20140329746-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2014-11-06 US disclosed
US-20140329746-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2014-11-06 US disclosed
CN-102574915-B Antibodies that specifically bind to Abeta oligomers and uses thereof IMMUNAS PHARMA, INC. (JP) 2014-10-22 CN disclosed
US-20140295329-A1 HOLOGRAPHIC MEDIUM HAVING A PROTECTIVE LAYER BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-10-02 US disclosed
US-8835654-B2 Method and compositions for treating amyloid-related diseases BHI LIMITED PARTNERSHIP (CA) 2014-09-16 US disclosed
US-8835654-B2 Method and compositions for treating amyloid-related diseases BHI LIMITED PARTNERSHIP (CA) 2014-09-16 US disclosed
US-8835654-B2 Method and compositions for treating amyloid-related diseases BHI LIMITED PARTNERSHIP (CA) 2014-09-16 US disclosed
CN-103946325-A Aqueous coating compositions CYTEC AUSTRIA GMBH 2014-07-23 CN disclosed
WO-2014078729-A1 IONIC STRENGTH-MEDIATED pH GRADIENT ION EXCHANGE CHROMATOGRAPHY GENENTECH, INC. (US) 2014-05-22 WO disclosed
EP-2721681-A1 METHODS OF PRODUCING SULFATE SALTS OF CATIONS FROM HETEROATOMIC COMPOUNDS AND DIALKYL SULFATES AND USES THEREOF Fluidic, Inc. (US) 2014-04-23 EP disclosed
EP-2683817-A2 THERMOSTABLE CARBONIC ANHYDRASES AND METHODS OF USE THEREOF Danisco US Inc. (US) 2014-01-15 EP disclosed
CN-103068881-A Polylactic acid block copolymer TORAY INDUSTRIES 2013-04-24 CN disclosed
CN-103068880-A Method for producing polylactic acid block copolymer TORAY INDUSTRIES 2013-04-24 CN disclosed
WO-2012154735-A9 THERMOSTABLE CARBONIC ANHYDRASES AND METHODS OF USE THEREOF DANISCO US INC. (US) 2013-04-18 WO disclosed
WO-2012174531-A1 METHODS OF PRODUCING SULFATE SALTS OF CATIONS FROM HETEROATOMIC COMPOUNDS AND DIALKYL SULFATES AND USES THEREOF FLUIDIC, INC. (US) 2012-12-20 WO disclosed
WO-2012154735-A2 THERMOSTABLE CARBONIC ANHYDRASES AND METHODS OF USE THEREOF DANISCO US INC. (US) 2012-11-15 WO disclosed
CN-102596997-A Antibodies that specifically bind to A beta oligomers and use thereof IMMUNAS PHARMA INC 2012-07-18 CN disclosed
CN-102574915-A Antibodies that specifically bind to Abeta oligomers and uses thereof IMMUNAS PHARMA INC 2012-07-11 CN disclosed
CN-102459335-A Antibodies that specifically bind to Abeta oligomers and uses thereof IMMUNAS PHARMA INC 2012-05-16 CN disclosed
WO-2012037150-A1 CRYSTAL STRUCTURES OF O-GLCNAC TRANSFERASE AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-03-22 WO disclosed
US-20120015911-A1 METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES BELLUS HEALTH INC. (CA) 2012-01-19 US disclosed
US-20120015911-A1 METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES BELLUS HEALTH INC. (CA) 2012-01-19 US disclosed
US-20120015911-A1 METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES BELLUS HEALTH INC. (CA) 2012-01-19 US disclosed
US-20110294911-A1 POLYURETHANE SURFACTANT STABILIZED POLYURETHANE FOAMS BAYER MATERIALSCIENCE AG (DE) 2011-12-01 US disclosed
US-20110275728-A1 DISPERSED TWO-COMPONENT POLYURETHANE FOAMS BAYER MATERIALSCIENCE AG (DE) 2011-11-10 US disclosed
US-8044100-B2 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH INC. (CA) 2011-10-25 US disclosed
US-8044100-B2 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH INC. (CA) 2011-10-25 US disclosed
US-8044100-B2 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH INC. (CA) 2011-10-25 US disclosed
US-20110171277-A1 WOUND DRESSING HAVING A POLYURETHANE FOAM LAYER AND A COVER LAYER MADE OF THERMOPLASTIC POLYMER BAYER MATERIALSCIENCE AG (DE) 2011-07-14 US disclosed
CN-102124105-A Antibody capable of specifically binding to Abeta oligomer and application thereof IMMUNAS PHARMA INC 2011-07-13 CN disclosed
CN-101080429-B Water-based coating compositions comprising thiol-functional compounds AKZO NOBEL COATINGS INT BV 2010-10-13 CN disclosed
CN-101117468-B Ink-jet ink, method for preparing the ink-jet ink RICOH KK 2010-09-22 CN disclosed
EP-2222350-A2 BIOMEDICAL FOAM ARTICLES Bayer Innovation GmbH (DE) 2010-09-01 EP disclosed
CN-1753961-B Cmp composition comprising a sulfonic acid and a method for polishing noble metals CABOT MICROELECTRONICS CORP 2010-08-11 CN disclosed
EP-2197931-A2 POLYURETHANE FOAMS FOR WOUND MANAGEMENT Bayer Innovation GmbH (DE) 2010-06-23 EP disclosed
US-20090263431-A1 POLYURETHANE FOAMS FOR WOUND MANAGEMENT BAYER INNOVATION GMBH (DE) 2009-10-22 US disclosed
CN-101511897-A Aqueous compositions of sagging control agents DU PONT (US) 2009-08-19 CN disclosed
EP-2078041-A2 FUSION PROTEINS COMPRISING TWO OR MORE IGG BINDING DOMAINS OF STREPTOCOCCAL PROTEIN G. Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2009-07-15 EP disclosed
US-20090155779-A1 APTAMERS THAT BIND TO PRION PROTEIN THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-06-18 US disclosed
WO-2009043498-A2 POLYURETHANE FOAMS FOR WOUND MANAGEMENT BAYER INNOVATION GMBH (DE) 2009-04-09 WO disclosed
WO-2009043499-A2 BIOMEDICAL FOAM ARTICLES BAYER INNOVATION GMBH (DE) 2009-04-09 WO disclosed
US-20090092647-A1 POLYURETHANE FOAMS FOR WOUND MANAGEMENT BAYER MATERIALSCIENCE AG (DE) 2009-04-09 US disclosed
CN-100475957-C Novel gluconate dehydratase MITSUI CHEMICALS INC (JP) 2009-04-08 CN disclosed
US-20090054542-A1 EO/PO BLOCK COPOLYMERS USEFUL AS STABILIZERS FOR PUR FOAMS BAYER MATERIALSCIENCE AG (DE) 2009-02-26 US disclosed
CN-101313042-A Compositions and methods for chemical mechanical polishing of tantalum CABOT MICROELECTRONICS CORP (US) 2008-11-26 CN disclosed
EP-1844141-A4 METHOD FOR SEPARATING AND PURIFYING NUCLEIC ACID FUJIFILM CORP (JP) 2008-11-05 EP disclosed
WO-2008035217-A2 FUSION PROTEINS COMPRISING TWO OR MORE IGG BINDING DOMAINS OF STREPTOCOCCAL PROTEIN G. INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2008-03-27 WO disclosed
EP-1896850-A2 APTAMERS THAT BIND TO PRION PROTEIN The Ohio State University Research Foundation (US) 2008-03-12 EP disclosed
CN-101128421-A Methods and compositions for treating amyloid-related diseases NEUROCHEM INTERNAT LTD (CH) 2008-02-20 CN disclosed
CN-101117468-A Ink-jet ink, method for preparing the ink-jet ink RICOH KK (JP) 2008-02-06 CN disclosed
CN-101080429-A Water-based coating compositions comprising thiol-functional compounds AKZO NOBEL COATINGS INT BV (NL) 2007-11-28 CN disclosed
EP-1853705-A1 METHOD FOR SEPARATING AND PURIFYING NUCLEIC ACID Fujifilm Corporation (JP) 2007-11-14 EP disclosed
EP-1853704-A1 METHOD FOR SEPARATING AND PURIFYING NUCLEIC ACID Fujifilm Corporation (JP) 2007-11-14 EP disclosed
EP-1844141-A1 METHOD FOR SEPARATING AND PURIFYING NUCLEIC ACID FUJIFILM Corporation (JP) 2007-10-17 EP disclosed
EP-1844140-A1 METHOD FOR PREPARING SAMPLE SOLUTION AND SAMPLE SOLUTION PREPARING APPARATUS FUJIFILM Corporation (JP) 2007-10-17 EP disclosed
WO-2006138676-A2 APTAMERS THAT BIND TO PRION PROTEIN THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2006-12-28 WO disclosed
US-20060223855-A1 reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2006-10-05 US disclosed
WO-2006093325-A1 METHOD FOR SEPARATING AND PURIFYING NUCLEIC ACID FUJIFILM CORPORATION (JP) 2006-09-08 WO disclosed
WO-2006093330-A1 METHOD FOR SEPARATING AND PURIFYING NUCLEIC ACID FUJIFILM CORPORATION (JP) 2006-09-08 WO disclosed
WO-2006083017-A1 METHOD FOR SEPARATING AND PURIFYING NUCLEIC ACID FUJIFILM CORPORATION (JP) 2006-08-10 WO disclosed
WO-2006080579-A1 METHOD FOR PREPARING SAMPLE SOLUTION AND SAMPLE SOLUTION PREPARING APPARATUS FUJIFILM CORPORATION (JP) 2006-08-03 WO disclosed
US-20060078745-A1 Formable composite films of plastic and composite elements of plastic coated with soft touch coating, and the production thereof BAYER MATERIALSCIENCE AG 2006-04-13 US disclosed
CN-1753961-A Cmp composition comprising a sulfonic acid and a method for polishing noble metals CABOT MICROELECTRONICS CORP (US) 2006-03-29 CN disclosed
CN-1597942-A Novel gluconate dehydratase MITSUI CHEMICALS INC (JP) 2005-03-23 CN disclosed
CN-1134539-C Thrombopoietin ��Ĭɭ�����ѧ���޹�˾ 2004-01-14 CN disclosed
US-6638503-B2 Extraction of actinokinase MAHARASHTRA ASSOCIATION FOR THE CULTIVATION OF SCIENCE (IN) 2003-10-28 US disclosed
US-20030170221-A1 STREPTOMYCES MEGASPORUS SD5, PROCESS FOR THE ISOLATION THEREOF, NOVEL FIBRINOLYTIC ENZYME PREPARED THEREFROM, PROCESS FOR THE PRODUCTION OF SAID ENZYME AND METHOD OF TREATMENT OF THROMBOLYTIC DISORDERS USING SAID ENZYME MAHARASHTRA ASSOC. FOR THE CULTIVATION OF SCIENCE 2003-09-11 US disclosed
WO-1998001550-A2 VACCINE AGAINST GASTRO-INTESTINAL NEMATODES UNIVERSITEIT UTRECHT (NL) 1998-01-15 WO disclosed
CN-1141061-A Thrombopoietin GENENTECH INC (US) 1997-01-22 CN disclosed
CN-1114358-A Isolation, quantitation and purification of insecticidal proteins from endotoxins of bacillus thuringiensis CA NAT RESEARCH COUNCIL (CA) 1996-01-03 CN disclosed
US-5460948-A Enzymatically converting salicylate to a catechol, reacting the catechol with 4-aminophenazone to produce a dye; colorimetric, quantiatative analysis THE PUBLIC HEALTH LABORATORY SERVICE BOARD (GB) 1995-10-24 US disclosed
EP-0396584-B1 ASSAY OF SALICYLATES OR REDUCED PYRIDINE NUCLEOTIDES MICROBIOLOGICAL RES AUTHORITY (GB) 1995-01-25 EP disclosed
EP-0396584-A1 ASSAY OF SALICYLATES OR REDUCED PYRIDINE NUCLEOTIDES. HEALTH LAB SERVICE BOARD (GB) 1990-11-14 EP disclosed
WO-1989005356-A1 ASSAY OF SALICYLATES OR REDUCED PYRIDINE NUCLEOTIDES THE PUBLIC HEALTH LABORATORY SERVICE BOARD (GB) 1989-06-15 WO disclosed
JP-S62175668-A METHOD OF MEASURING CALCIUM SHINOTESUTO KENKYUSHO:KK 1987-08-01 JP disclosed
EP-0224162-A2 Photosensitive polycondensation product containing diazonium groups, their production process and photosensitive registration material containing this polycondensate HOECHST AKTIENGESELLSCHAFT (DE) 1987-06-03 EP disclosed
EP-0224162-A2 Photosensitive polycondensation product containing diazonium groups, their production process and photosensitive registration material containing this polycondensate HOECHST AKTIENGESELLSCHAFT (DE) 1987-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223855-A1 reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity APP, IAPP, BACE1 EPHX1 812/4885TP53 1511/4885KDM4E 4831/4885
US-20090263431-A1 POLYURETHANE FOAMS FOR WOUND MANAGEMENT FGB, F2, F8 EPHX1 1950/4885TP53 2598/4885KDM4E 1689/4885
US-20140329746-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES APP, PSEN1, PSEN2 EPHX1 574/4885TP53 1545/4885KDM4E 4713/4885
US-20110171277-A1 WOUND DRESSING HAVING A POLYURETHANE FOAM LAYER AND A COVER LAYER MADE OF THERMOPLASTIC POLYMER PUF60, KRT18, CUTA EPHX1 780/4885TP53 1814/4885KDM4E 3475/4885
US-20120015911-A1 METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES APP, PSEN1, PSEN2 EPHX1 592/4885TP53 2048/4885KDM4E 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.